Skip to main content
Premium Trial:

Request an Annual Quote

IBM, CLC Bio Team on Sequencing Analytics

NEW YORK (GenomeWeb News) – IBM and CLC Bio announced today that they will offer a trunkey next-generation sequencing data analytics solution that combines their respective products.

The offering will combine IBM hardware, including its System x 3550 M4 rack servers, CLC's Genomics Server software for large-scale genomics sequencing data analysis, and CLC's Genomics Workbench for analyzing, comparing, and visualizing high-throughput sequencing data.

"It is imperative that we serve our customers with a platform that is easy to deploy and support, delivering the power to perform their next generation sequencing workload," Janis Landry-Lane, director of worldwide deep computing at IBM, said in a statement. "Molecular biologists and clinicians need these tools to realize the promise of personalized medicine."

The turnkey platform comes in three different configurations, the firms said, ranging from 48 CPU cores and 192 GBs of memory to 192 CPU cores and 768 GBs of memory, depending on the requirements of the individual customer.

Further terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.